Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C42H58O6 |
Molecular Weight | 658.9063 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 9 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)O[C@H]1CC(C)(C)C(=C=C\C(C)=C\C=C\C(C)=C\C=C\C=C(C)\C=C\C=C(/C)C(=O)C[C@@]23O[C@]2(C)C[C@@H](O)CC3(C)C)[C@](C)(O)C1
InChI
InChIKey=SJWWTRQNNRNTPU-XJUZQKKNSA-N
InChI=1S/C42H58O6/c1-29(18-14-19-31(3)22-23-37-38(6,7)26-35(47-33(5)43)27-40(37,10)46)16-12-13-17-30(2)20-15-21-32(4)36(45)28-42-39(8,9)24-34(44)25-41(42,11)48-42/h12-22,34-35,44,46H,24-28H2,1-11H3/b13-12+,18-14+,20-15+,29-16+,30-17+,31-19+,32-21+/t23-,34-,35-,40+,41+,42-/m0/s1
Molecular Formula | C42H58O6 |
Molecular Weight | 658.9063 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 5 / 5 |
E/Z Centers | 9 |
Optical Activity | UNSPECIFIED |
Fucoxanthin isis a marine carotenoid mainly found in brown algae, giving them a brown or olive-green color. Fucoxanthin is investigated for its anti-inflammatory, antinociceptive and anti-cancer effects. In vivo studies have demonstrated that oral administration of fucoxanthin inhibited carcinogenesis in an animal model of duodenal, skin, colon and liver cancer. Fucoxanthin causes antitumor and anticarcinogenic effects by inducing G1 cell-cycle arrest and apoptosis by modulating expression of various cellular molecules and cellular signal transduction pathways, but the exact mechanism of anti-cancer action of fucoxanthin is not fully elucidated. Fucoxanthin regulates lipids metabolism, the effect most likely mediated by AMK-activated protein kinase. A clinical trial of fucoxanthin against non-alcoholic fatty liver disease is ongoing.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:1904177 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15896707 |
|||
Target ID: map04151 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28928905 |
|||
Target ID: map04010 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28928905 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02875392
In a clinical trial against non-alcoholic fatty liver disease fucoxanthin is administered orally as a component of FucoHiQ capsules. Each serving contains 275 mg of fucoxanthin, 6 capsules per day are administered.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28212270
Human non-small cell lung cancer cells were treated with 12.5-100 uM of fucoxanthin for 24-72 hours. Cytotoxic activity was evaluated by the Cell counting kit-8 and the absorbance was measured at 450 nm.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 03:05:43 GMT 2023
by
admin
on
Sat Dec 16 03:05:43 GMT 2023
|
Record UNII |
06O0TC0VSM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
664 (Number of products:35)
Created by
admin on Sat Dec 16 03:05:43 GMT 2023 , Edited by admin on Sat Dec 16 03:05:43 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
FUCOXANTHIN
Created by
admin on Sat Dec 16 03:05:43 GMT 2023 , Edited by admin on Sat Dec 16 03:05:43 GMT 2023
|
PRIMARY | |||
|
SUB60248
Created by
admin on Sat Dec 16 03:05:43 GMT 2023 , Edited by admin on Sat Dec 16 03:05:43 GMT 2023
|
PRIMARY | |||
|
5186
Created by
admin on Sat Dec 16 03:05:43 GMT 2023 , Edited by admin on Sat Dec 16 03:05:43 GMT 2023
|
PRIMARY | |||
|
C025164
Created by
admin on Sat Dec 16 03:05:43 GMT 2023 , Edited by admin on Sat Dec 16 03:05:43 GMT 2023
|
PRIMARY | |||
|
100000134210
Created by
admin on Sat Dec 16 03:05:43 GMT 2023 , Edited by admin on Sat Dec 16 03:05:43 GMT 2023
|
PRIMARY | |||
|
DB15462
Created by
admin on Sat Dec 16 03:05:43 GMT 2023 , Edited by admin on Sat Dec 16 03:05:43 GMT 2023
|
PRIMARY | |||
|
06O0TC0VSM
Created by
admin on Sat Dec 16 03:05:43 GMT 2023 , Edited by admin on Sat Dec 16 03:05:43 GMT 2023
|
PRIMARY | |||
|
m5580
Created by
admin on Sat Dec 16 03:05:43 GMT 2023 , Edited by admin on Sat Dec 16 03:05:43 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID901031617
Created by
admin on Sat Dec 16 03:05:43 GMT 2023 , Edited by admin on Sat Dec 16 03:05:43 GMT 2023
|
PRIMARY | |||
|
3351-86-8
Created by
admin on Sat Dec 16 03:05:43 GMT 2023 , Edited by admin on Sat Dec 16 03:05:43 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> ACTIVE CONSTITUENT ALWAYS PRESENT |
Unit; ng/g; The content of carotenoids from selected commercially available health supplements (Spirulina)
ASSAY (HPLC)
Batch Data
|